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Abstract  
Introduction: Asthma is one of acute respiratory diseases leading to emergency department (ED) referral. 
Management of acute attack plays an important role in its outcome.  
Objective: This trial was designed to evaluate the effectiveness of nebulized budesonide versus placebo in 
moderate to severe acute asthma attack in adults in the ED.  
Method: In this clinical trial, we enrolled patients with acute exacerbation of asthma and standard treatment 
of acute asthma attack was administered to all of them. 41 patients in our study were randomly entered into 2 
groups. In one group, we prescribed nebulized budesonide and in the other group nebulized placebo (normal 
saline) was administered. Patients’ demographic data, vital signs, symptoms’ acuity and the time of symptom 
relief, patient and physician satisfaction were all recorded and compared between the 2 groups. All cases were 
followed and disease outcome, readmission, mortality and morbidity rates were documented. 
Results: In this study, 20 patients were entered the budesonide group and 19 patients were enrolled in the 
placebo group. The mean age ranges were 55.70±15.30 and 60.32±18.41 years old respectively. Heart rate, 
respiratory rate and O2 saturation in the first group were improved significantly after the treatment in 
comparison to the second group (p<0.05). The mean time of recovery and length of hospital stay were better 
in the first group than the second group but this difference was not significant (p>0.05). 
Conclusion: The addition of nebulized budesonide to standard asthma treatment might result in more 
improvement in O2 saturation and less patient’s distress. 
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INTRODUCTION
Acute asthma attack is one of the reasons, patients 
refer to the emergency department (ED). Most 
patients are admitted to the ED in the acute phase 
and their treatment is focused on relief of 
bronchospasm by short acting 2 agonist (SABA) 
and anticholinergic (ipratropium bromide) as 
inhaled bronchodilators, decrease in airway 
inflammation and also preventing recurrence of 
acute symptoms by systemic and inhaled 
corticosteroid (ICS) (1). 
Systemic corticosteroids or ICSs seemed to be 
ineffective long ago, but many studies have 
confirmed that they could have an early treatment 
effect. This role consists of genomic and 
nongenomic effects which the later includes 
binding to membrane and cytoplasmic 
corticosteroid receptors. This binding leads to 
prohibiting norepinephrine (NEP) reuptake in the 
neuromuscular junction thus NEP density 
increases bronchodilation and decreases mucosal 
blood flow in asthmatic patients. The nongenomic 
effect is really fast over the very first seconds to 
minutes (1). 
ICS like budesonide is one of asthma symptoms’ 
controller by reducing airway inflammation and 
mediators involved. This can lead to better lung 
function, less admission and more desirable life 
style. Budesonide, a synthetic highly potent ICS, has 
been studied in children suffering acute asthma 
attack as different forms of inhaler and nebulized 
suspension (2-4). 
Based on asthma prevalence rate of 1 to 18% in 
different countries, emergency physicians (EPs) 
should prescribe drugs with the best effectiveness 
in the earliest moments of disease exacerbation. 
Many studies have supported the usage of 
combination therapy of SABA and ICS in increasing 
recovery rate and decreasing treatment time (2, 5). 
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Most studies about the effectiveness of nebulized 
budesonide are performed on children and in mild 
or chronic asthma (4, 6-9). In this study, we decided 
to evaluate its efficacy in adults and in the acute 
phase in the emergency setting. 
METHODS 
Study design 
This study was a double blind randomized clinical 
trial (RCT) done in the EDs of 2 tertiary referral 
centers of university hospitals in 2018. The study 
was approved by the ethics committee and it was 
registered in www.irct.ir with the trial number of 
IRCT20170325033132N3. All patients were 
interviewed and the method of drug 
administration and possible complications were 
explained to them and informed written consent 
was obtained.  
Study population 
All adult patients with moderate to severe acute 
asthma attack were enrolled in our study. The 
sampling was convenient and we used block 
randomization. We enrolled 41 patients based on 
our inclusion criteria; age older than 18 years old, 
moderate to severe acute asthma attack, known 
cases of asthma referring to the ED. Asthma attack 
was diagnosed by deterioration of symptoms from 
baseline and exacerbation needed early 
intervention. Our exclusion criteria were new cases 
of asthma, asthma accompanied by another 
diagnosis like pneumonia, congestive heart failure 
(CHF), pneumothorax or any other systemic or 
structural lung diseases, altered mentation or 
confusion, sever respiratory failure with cyanosis, 
intubated patients, illicit drug addiction, 
pregnancy, unstable vital signs, drug allergy and 
unwillingness to enter the study. The rate of clinical 
recovery was considered as the main variable. 
Based on Blic et al study,5 in order to show 50% 
increase in the recovery rate and by considering 
10% loss of our samples, we calculated a sample 
size of 20 cases in each group (=0.05 and 
power=90%). 
Intervention 
All patients received standard asthma attack 
treatment, O2 therapy, SABA and Atrovent spray 
(4-10 puffs each 20 min during the first hour) and 
intravenous systemic corticosteroid (100 mg 
hydrocortisone) were administered to them. 
Patients were randomly enrolled in either the 
 
Figure 1: CONSORT flowchart of the participants in the study 
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control group (nebulized budesonide brand name 
pulmicort made by AstraZeneca company) or 
placebo group (nebulized normal saline). In the 
control group, nebulized budesonide was 
prescribed 0.5 mg every half an hour till 3 doses 
(1.5 mg total dose) and in the placebo group the 
equivalent normal saline was nebulized at the same 
time. All patients underwent cardiac and 
respiratory monitoring during the treatment. 
At the time of admission and before the treatment 
was started, the severity of asthma was evaluated 
by peak flowmeter. All patients with moderate to 
severe asthma attack [based of peak expiratory 
flow rate (PEFR)], were enrolled in the study and 
accurate medical history, physical exam 
(auscultation of wheeze, its severity, time and 
location, respiratory accessory muscle use), vital 
signs including heart rate (HR), respiratory rate 
(RR) and O2 saturation (SPO2) were evaluated and 
recorded at baseline and also at 30 min, 1 and 3 
hours after the intervention. 
Primary and Secondary Endpoints 
Our primary endpoint was to compare the 
effectiveness of nebulized budesonide versus 
placebo in adults with asthma attack in the ED by 
evaluating their vital signs, and physical 
examination. Our secondary endpoints were 
comparing hospital length of stay, patients and 
physicians’ satisfaction, recurrence, readmission 
and mortality rates, the mean time of recovery and 
admission during 1 month follow up. 
Statistical Analysis 
The data are presented as mean values or 
proportions, and differences in these values are 
presented with accompanying 95% confidence 
intervals (CI). Variables were tested for normality 
by Kolmogorov–Smirnov test before analysis. 
Analytical statistical tests included the unpaired, 
two-tailed t-test for continuous normally 
distributed data and the Mann–Whitney U test for 
non-normal and ordinal data. The chi-square and 
Fisher’s exact tests were used to compare 
proportions of the qualitative variables. We also 
used repeated measure AVOVA. The level of 
significance was 0.05. SPSS for Windows software 
(version 22) was used for all data analysis. 
RESULTS 
Forty-eight patients were eligible in our study of 
whom 7 cases were excluded: 4 were smokers, 1 
CHF, 1 pneumonia, 1 allergy history. Finally, 41 
patients were enrolled in our study; 22 cases in the 
control group and 19 in the placebo group (figure 
1). Two patients in the control group had lost to 
follow up thus we eventually evaluated 20 patients 
in the control group and 19 patients in the placebo 
group. The mean age in the control group was 
55.7015.30 and in the control group was 
60.3218.41 years old. There were 10 males in 
each group but we evaluated 10 females in the 
control group and 9 in the placebo group. Baseline 
PEFR showed no difference in asthma severity 
between the 2 groups. Data are shown in table 1.  
HR had a significant reduction within each group 
and this reduction was significantly more in the 
control group (p=0.04). RR also showed the same 
change (p=0.03). SPO2 increased significantly 
within each group and this improvement was 
significantly more in the control group (p=0.01). 
These results showed that patients in the control 
group experienced significantly less distress in 
comparison to the placebo group. In the placebo 
group, 1 patient still had severe wheeze 3 hours 
after the intervention. In contrast, all patients’ 
wheeze was completely relieved 1 hour after the 
treatment in control group. However, this 
difference was not statistically significant. Data of 
our primary endpoints are shown in table 2.  
Our results failed to show any significant difference 
in patient or physician satisfaction between the 2 
groups. Recurrence or readmission or mortality 
had similar rate between the 2 groups. Data are 
shown in table 3. 
The mean time of recovery in the control and 
placebo group were 41.683.16 and 60.252.04 
min, respectively (p= 0.12). The mean length of 
hospital stay in the control and placebo group were 
3.8 and 4.5 days, respectively (p=0.53).  
DISCUSSION 
Based on the findings of current study, nebulized 
budesonide in adult acute asthma crisis might be 
effective in reducing patient respiratory distress by 
ameliorating HR, RR and SPO2. Nevertheless, it 
could not decrease recovery time or length of 
hospital stay and also long term outcomes 
including recurrence or readmission. 
Edmonds et al performed a meta-analysis about the 
effectiveness of ICS in emergency setting. They 
Table 1: Baseline information of studied patients 
Variable Control Placebo P 
Age (y/old) 55.7015.30 60.3218.41 0.06 
Gender (N (%))    
Male 10 (50%) 10 (52%) 
0.86 
Female 10 (50%) 9 (48%) 
PEFR (N (%))    
40-70% 12 (60%) 11 (58%) 
0.89 
<40% 8 (40%) 8 (42%) 
PEFR: Peak flowmetry 
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evaluated clinical trials done on both children and 
adults. In 2 of these studies, ICS was compared to 
placebo like our study. They found that patients 
treated with ICS had significantly less admission 
rate but we did not find the same result. In 
conclusion this meta-analysis revealed that 
although ICS reduced admission rate, but further 
studies in this field should be designed (9). 
Adding ICS, as inhalers by meter dose inhalers 
(MDIs) or nebulized forms, to systemic 
corticosteroids failed to show any significant 
differences in the flow rate or other primary 
clinical outcomes (10, 11). Our study showed that 
except HR, RR and SPO2 no significant difference 
was observed between the 2 groups.  
In an RCT published in CHEST journal in 2006, 470 
adult patients and 663 children with asthma were 
evaluated. In this research, ICS was compared with 
placebo. They found that cases who received 3 or 
more doses of ICS had a significantly better 
improvement in clinical signs and also spirometry 
(1). 
In START study the efficacy of ICS as a routine 
therapy in persistent mild asthma was determined. 
Both adults and children received daily budesonide 
for 2 years. Authors concluded that early 
prescription of ICS could prevent severe asthma 
attack and reduce the need for more drugs (9). Our 
study was performed in the acute setting in 
moderate to severe asthma and we observed 
higher SPO2 and lesser distress in our patients. 
Devidayal et al compared the effectiveness of 
inhaled budesonide versus oral prednisolone in the 
ED and in children with acute asthma. They 
revealed the same results as our adult patients. 
They showed that HR, RR, SPO2 and respiratory 
distress were significantly improved in the 
budesonide group (12). 
MacLaughlin et al evaluated the risk of readmission 
in the ED in children younger than 8-year-old who 
had received nebulized budesonide. They 
demonstrated that budesonide decrease 
recurrence and readmission rates significantly up 
to 71% (13). We did not document the same 
results. 
Limitations 
One limitation of our study was that the sample size 
might be insufficient to detect the exact drug 
effects. Further clinical trials with larger sample 
sizes and longer follow-up should therefore be 
performed to identify its role. It was difficult to 
follow patients during 1 month, some of our 
patients were unwilling to answer our questions or 
refer for frequent visits. This was the results of 2 
tertiary referral centers and might not be 
extendable to other centers.  




0 min 30 min 60 min 180 min 
Systolic blood pressure (mmHg) 
Control 139.4225.40 130.0020.54 128.1620.56 126.5820.21 
0.32 
Placebo 150.4723.79 148.4721.15 142.3718.73 138.9517.99 
Diastolic blood pressure (mmHg) 
Control 82.5312.19 76.8412.04 76.8410.43 76.328.30 
0.31 
Placebo 87.0512.28 85.6813.08 81.117.88 79.266.47 
Heart rate (beats/min) 
Control 108.6024.12 102.0523.43 94.7522.81 91.2520.92 
0.04 
Placebo 100.3724.83 97.2122.85 94.3722.05 92.1620.53 
Respiratory rate (n/min) 
Control 34.607.46 27.105.66 23.354.91 21.006.64 
0.03 
Placebo 30.119.87 29.112.35 28.112.73 27.111.29 
O2 saturation (%) 
Control 84.058.56 90.105.54 94.303.52 95.851.87 
0.01 
Placebo 88.793.29 91.003.36 92.842.21 93.792.27 
wheeze (n (%)) 
Control 20 (100) 14 (70.0) 9 (45.0) 0 (0.0) 
0.48 
Placebo 19 (100) 13 (68.4) 9 (47.4) 1 (5.3) 
Severe wheeze (n (%)) 
Control 13 (65.0) 4 (28.6) 1 (11.1) 0 (0.0) 
0.12 
Placebo 7 (36.8) 5 (38.5) 3 (33.3) 0 (0.0) 
Respiratory accessory muscle use (n (%)) 
Control 9 (45.0) 5 (25.0) 2 (10.0) 0 (0.0) 
1.00 
Placebo 7 (36.8) 3 (15.8) 1 (5.3) 0 (0.0) 
 
Table 3: Comparison of the study secondary endpoints 
Variable 
Control group Placebo group 
P Yes No Yes No 
n (%) 
Patient satisfaction 18 (90%) 2 (10%) 13 (68%) 6 (32%) 0.12 
Physician satisfaction 17 (85%) 3 (15%) 12 (63%) 1 (37%) 0.15 
Recurrence rate 3 (17%) 15 (83%) 7 (37%) 12 (63%) 0.26 
Readmission rate 2 (11%) 16 (89%) 6 (32%) 13 (68%) 0.23 
Mortality rate 0 (0%) 20 (100%) 0 (0%) 19 (100%) - 
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CONCLUSIONS 
It is likely that, nebulized budesonide in adult acute 
asthma crisis might be effective in reducing patient 
respiratory distress; But, has not any significant 
effect on recovery time or length of hospital stay, or 
long term outcomes including recurrence or 
readmission or mortality. 
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